Sign In
Buy SRRK
$47.30
-1.70 (-3.46%)
At Close: Jul 31, 2026
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock announced a trials in progress poster presentation at the 2021 ASCO Annual Meeting, being held from June 4-8, 2021.
Scholar Rock Reports First Quarter 2021 Financial Results and Highlights Business Progress
07:30am, Thursday, 13'th May 2021
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundament
Scholar Rock Announces Issuance of U.S. Patent Broadly Relevant to Inhibitors of Myostatin Activation
04:59pm, Monday, 26'th Apr 2021
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock today announced that the United States Patent Office (USPTO) issued U.S. Patent No. 10,981,981 with an expiry of May 2034.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Scholar Rock Holding Corporation - SRRK
08:37pm, Wednesday, 21'st Apr 2021
New York, New York--(Newsfile Corp. - April 21, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Scholar Rock Holding Corporation ("Scholar Rock" or the "Company") (NASDAQ: SRRK
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Scholar Rock Holding Corporation - SRRK
11:17pm, Monday, 19'th Apr 2021
NEW YORK, April 19, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Scholar Rock Holding Corporation ("Scholar Rock" or the "Company") (NASDAQ: SRRK). Such i
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Scholar Rock Holding Corporation - SRRK
06:25am, Tuesday, 13'th Apr 2021
NEW YORK, April 13, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Scholar Rock Holding Corporation ("Scholar Rock" or the "Company") (NASDAQ: SRRK). Such i
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Scholar Rock Holding Corporation - SRRK
04:00am, Sunday, 11'th Apr 2021
NEW YORK, April 11, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Scholar Rock Holding Corporation ("Scholar Rock" or the "Company") (NASDAQ: SRRK). Such i
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock announced the publication of preclinical development data for SRK-181 in the peer-reviewed journal International Journal of Toxicology.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock announced its oral and poster presentations at the 2021 Muscular Dystrophy Association (MDA) Virtual Clinical & Scientific Conference
Scholar Rock Holding Corporation (SRRK) Reports Q4 Loss, Misses Revenue Estimates
06:57pm, Tuesday, 09'th Mar 2021
Scholar Rock Holding Corporation (SRRK) delivered earnings and revenue surprises of -27.42% and -53.27%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead
Analysts Estimate Scholar Rock Holding Corporation (SRRK) to Report a Decline in Earnings: What to Look Out for
01:40pm, Thursday, 04'th Mar 2021
Scholar Rock Holding Corporation (SRRK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Scholar Rock Announces Senior Management Promotions
04:30pm, Thursday, 04'th Feb 2021
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundament
Scholar Rock Presents Preclinical Data for SRK-181 at the TGFβ for Immuno-Oncology Drug Development Summit
08:00am, Wednesday, 27'th Jan 2021
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundament
Scholar Rock to Present at the 39th Annual J.P. Morgan Healthcare Conference
04:01pm, Monday, 04'th Jan 2021
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundament
2 Top Biotech Stocks From the IPO Class of 2018 to Buy Now
07:24am, Wednesday, 04'th Nov 2020
Compelling clinical trial results so far make these biotech stocks worth more attention than they've received so far.
